Registration from the business meeting of representatives of Eli Lilly with representatives of MZ SR

For the Ministry of Health of the Slovak Republic (hereinafter "the Ministry'):

• director of the Division of Classification and Pricing, Mgr. Miriam Vulevová, MBA

• officer of the Department of Classification and Pricing, PharmDr. Barbora Murányiová

For Eli Lilly

•  Dr Dana Böhm

The meeting took place at the request of Eli Liily's managing director Dr. Dana Böhm. The meeting was opened by the Director Classification division; and Price formations, Mgr. Miriam Vuleva, MBA.

The reason for requesting a meeting is to alert Eli Liily to the the fact of high supplements of Stratera after a review of reimbursement after inclusion generic medicinal products that suggest are not available for the SR patient.

Elli Lilly was interested in how they could currently be reduce the patient's supplement of Stratera. Based on current validity legislation currently MZSR cannot change the payment because in categorisation The list includes generic medicines containing the active substance Atomoxetine. a lower payment. The solution would be to reduce the price of a medicine that is not acceptable to the manufacturer of the product.

MzSR is known for the fact that Zentiva has requested MZSR the removal from the list of medicinal products containing the active substance Atomixetine Categorized medicinal products by application A3 31.12.2013 held reclaimed permissions on 2.2.2013 (SUKL page is a reported interruption) production until the expected date 30.1.2017). Subsequently the company Zentiva again lodges application A3 on 2.2.2017.

The conclusion of the meeting is that the MZSR will review the information on the planned the supply of generic medicines.